Shelley Chu, MD, PhD

Board Member

Dr. Shelley Chu is a Partner at Lightspeed Venture Partners. Shelley has led the firm’s new biotech investments in multiple Seed, Series A, and Crossover companies. To date, her investments across all stages, from seed to growth, have led to seven NDAs by the FDA, nine drug candidates in active clinical development, and 16 exits through M&As, IPOs, or partnerships. Shelley brings two decades of investing and operating experience in the biopharmaceutical industry, including most recently at Gilead Sciences, where she led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV. Her passion is working closely with entrepreneurs to navigate scientific, clinical, regulatory, business development, and commercial hurdles to bring innovative new medicines to market that address significant unmet medical needs.

Shelley holds a BA in Molecular Biology from Princeton University and an MD and a PhD in Biochemistry and Biophysics from UCSF.